Alto Neuroscience to Participate in Upcoming Investor Conferences
07 3월 2024 - 10:00PM
Business Wire
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced
that company management will participate in the following upcoming
investor conferences:
- Jefferies Biotech on the Bay Summit, March 12-13th: Alto
management will participate in one-on-one meetings with investors
during the conference.
- UBS Virtual CNS Day, March 18th: Amit Etkin, M.D.,
Ph.D., founder and chief executive officer, will participate in a
fireside chat on Monday, March 18, 2024, at 2:30 pm ET.
- Stifel 2024 Virtual CNS Days, March 19-20th: Dr. Etkin
will participate in a fireside chat on Wednesday, March 20, 2024,
at 11:30 am ET. Alto management will also participate in one-on-one
meetings with investors during the conference.
The fireside chats will be available via live webcast on the
Events and Presentations page in the Investors section of Alto’s
website and a replay will be available following the
presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company
with a mission to redefine psychiatry by leveraging neurobiology to
develop personalized and highly effective treatment options. Alto’s
Precision Psychiatry Platform™ measures brain biomarkers by
analyzing EEG activity, neurocognitive assessments, wearable data,
and other factors to better identify which patients are more likely
to respond to Alto product candidates. Alto’s clinical-stage
pipeline includes novel drug candidates in depression, PTSD,
schizophrenia, and other mental health conditions. For more
information, visit www.altoneuroscience.com or follow Alto on
X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307562812/en/
Investor Contact: Nick Smith
investors@altoneuroscience.com
Media Contact: Jordann Merkert
media@altoneuroscience.com
Alto Neuroscience (NYSE:ANRO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alto Neuroscience (NYSE:ANRO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024